JNJ 📈 Johnson & Johnson - Overview
Exchange: NYSE • Opening Hours • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4781601046
JNJ: Medicines, Medical Devices, Contact Lenses, Intraocular Lenses
Johnson & Johnson is a global healthcare leader that researches, develops, manufactures, and sells a wide range of products to improve human health and well-being. Through its Innovative Medicine segment, the company offers a diverse portfolio of prescription medications that cater to various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
These medications are designed to treat a broad spectrum of conditions, such as rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis, HIV/AIDS, mood disorders, neurodegenerative disorders, schizophrenia, prostate cancer, hematologic malignancies, lung cancer, bladder cancer, thrombosis, diabetes, and macular degeneration. The company distributes these products to healthcare professionals, hospitals, wholesalers, and retailers, ensuring that they reach patients who need them most.
The MedTech segment of Johnson & Johnson is focused on developing innovative medical devices and technologies that improve patient outcomes. This segment offers a range of Interventional Solutions, including electrophysiology products to treat heart rhythm disorders, as well as technologies to treat severe coronary artery disease and cardiogenic shock. Additionally, the company provides neurovascular care solutions for hemorrhagic and ischemic stroke, and an orthopaedics portfolio that supports hips, knees, trauma, spine, sports, and other procedures.
Furthermore, the MedTech segment offers advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures. The company is also a leading provider of contact lenses under the ACUVUE Brand, and TECNIS intraocular lenses for cataract surgery. Johnson & Johnson distributes its MedTech products to hospitals, physicians, nurses, eye care professionals, and clinics, ensuring that they are accessible to those who need them.
With a rich history dating back to 1886, Johnson & Johnson is headquartered in New Brunswick, New Jersey, and has established itself as a trusted and reliable partner in the healthcare industry. The company's commitment to innovation, quality, and customer satisfaction has earned it a reputation as a global leader in the healthcare sector.
Additional Sources for JNJ Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
JNJ Stock Overview
Market Cap in USD | 368,366m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 1944-09-24 |
JNJ Stock Ratings
Growth 5y | 37.8 |
Fundamental | 72.7 |
Dividend | 57.2 |
Rel. Performance vs Sector | -0.69 |
Analysts | 3.78/5 |
Fair Price Momentum | 142.33 USD |
Fair Price DCF | 209.49 USD |
JNJ Dividends
Dividend Yield 12m | 2.40% |
Yield on Cost 5y | 3.05% |
Dividends CAGR 5y | 4.62% |
Payout Consistency | 96.03% |
JNJ Growth Ratios
Growth Correlation 3m | -76.8% |
Growth Correlation 12m | 39.4% |
Growth Correlation 5y | 58.1% |
CAGR 5y | 4.93% |
CAGR/Mean DD 5y | 0.71 |
Sharpe Ratio 12m | 0.03 |
Alpha vs SP500 12m | -13.57 |
Beta vs SP500 5y weekly | 0.48 |
Volatility GJR Garch 1y | 16.62% |
Current Volume | 9061.3k |
Average Volume 20d | 7172.4k |
As of November 21, 2024, the stock is trading at USD 153.11 with a total of 9,061,274 shares traded.
Over the past week, the price has changed by -0.08%, over one month by -5.97%, over three months by -3.68% and over the past year by +4.53%.
Yes, based on ValueRay Fundamental Analyses, Johnson & Johnson (NYSE:JNJ) is currently (November 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 72.69 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JNJ as of November 2024 is 142.33. This means that JNJ is currently overvalued and has a potential downside of -7.04%.
- Strong Buy: 8
- Buy: 2
- Hold: 13
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, JNJ Johnson & Johnson will be worth about 155.1 in November 2025. The stock is currently trading at 153.11. This means that the stock has a potential upside of +1.28%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 174.9 | 14.2% |
Analysts Target Price | 168.5 | 10% |
ValueRay Target Price | 155.1 | 1.3% |